Search fresh public links, source activity, and ready-to-use post angles for Asco.
Fresh curated links around ASCO are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Why I’m So Down on ASCO Anonymous (not verified) Mon, 06/01/2026 - 14:43 pharmagather item url Why I’m So Down on ASCO pharmagather item...
Leading researchers, clinicians, and healthcare professionals will gather this June at the American Society of Clinical Oncology’s (ASCO) Breakthrough meeting to discuss the opport...
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that w...
The American Society of Clinical Oncology (ASCO) and Ryght AI are teaming up to identify research sites for an ASCO clinical trial evaluating starting doses of CDK4/6 inhibitors in...
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line l...
CHICAGO — Low-dose aspirin during adjuvant chemotherapy did not significantly reduce risk for recurrence among unselected patients with stage III colorectal cancer, according to ra...
From: oncnursingnews.com The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has brought transformative data for the treatment of metastatic triple-negative breast...
Logistics and materials management company ASCO has opened its first office in the Middle East, establishing a presence in Qatar as it looks to expand its regional operations and s...
The American Society of Clinical Oncology (ASCO) 2026 Annual Meeting brought together more than 40,000 professionals at McCormick Place in Chicago May 29 through June 2 to explore...
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with Keytruda slashed the risk of disease progression or death by a whoppi...
Cardiff Oncology has shared updated results from its phase 2 colorectal cancer trial, revealing that the study drug has yet to reach the median progression-free survival as the bio...
The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has shown strong phase 3 results from China that suggest it could put up a fight against blockbuster TROP...
CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinica...
ASCO: Will New Drugs Demonstrate Benefits Over Generics? Anonymous (not verified) Sun, 05/31/2026 - 14:42 pharmagather item url ASCO: Will New Drugs Demons...
75.0% Response Rate and Median PFS of 10.9 Months Observed in First-Line Recurrent or Metastatic Head and Neck Cancer(R/M HNSCC)Advancing Tosposertib Toward Next-Stage Development...
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data dro...
CHICAGO, May 31, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-...
Labiotech heard from experts about the major trends and highlights in cancer care at ASCO 2026. The post Highlights of ASCO 2026: how is cancer care evolving? appeared first on L...
While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual meeting by conquering the “undruggable” RAS pathway, another up-and-coming biotech hop...
CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Onco...
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.